Ticker
AGEN

Price
3.00
Stock movement down
-0.04 (-1.32%)
Company name
Agenus Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
848.58M
Ent value
1.01B
Price/Sales
2.74
Price/Book
53.99
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-10.98%
3 year return
-9.44%
5 year return
-4.36%
10 year return
-1.92%
Last updated: 2022-11-24

DIVIDENDS

AGEN does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF1703.97
Price to FCF-
Price to EBITDA13.06
EV to EBITDA15.61

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales2.74
Price to Book53.99
EV to Sales3.27

FINANCIALS

Per share

Loading...
Per share data
Current share count282.86M
EPS (TTM)-0.09
FCF per share (TTM)-0.22

Income statement

Loading...
Income statement data
Revenue (TTM)309.89M
Gross profit (TTM)69.78M
Operating income (TTM)67.17M
Net income (TTM)-23.43M
EPS (TTM)-0.09
EPS (1y forward)-0.64

Margins

Loading...
Margins data
Gross margin (TTM)22.52%
Operating margin (TTM)21.68%
Profit margin (TTM)-7.56%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash247.71M
Net receivables1.29M
Total current assets290.48M
Goodwill24.62M
Intangible assets7.75M
Property, plant and equipment0.00
Total assets441.31M
Accounts payable34.54M
Short/Current long term debt64.31M
Total current liabilities163.06M
Total liabilities413.65M
Shareholder's equity15.72M
Net tangible assets231.36M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)498.00K
Capital expenditures (TTM)55.16M
Free cash flow (TTM)-54.67M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-149.03%
Return on Assets-5.31%
Return on Invested Capital-149.03%
Cash Return on Invested Capital-347.79%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open3.03
Daily high3.07
Daily low2.97
Daily Volume2.56M
All-time high315.75
1y analyst estimate9.67
Beta1.08
EPS (TTM)-0.09
Dividend per share-
Ex-div date-
Next earnings date27 Feb 2023

Downside potential

Loading...
Downside potential data
AGENS&P500
Current price drop from All-time high-99.05%-15.76%
Highest price drop-99.59%-56.47%
Date of highest drop14 Jun 20229 Mar 2009
Avg drop from high-92.69%-11.46%
Avg time to new high1913 days13 days
Max time to new high5716 days1805 days
COMPANY DETAILS
AGEN (Agenus Inc) company logo
Marketcap
848.58M
Marketcap category
Small-cap
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Employees
441
SEC filings
CEO
Garo H. Armen
Country
USA
City
Lexington
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Overall response rate (ORR) of 46% and disease control rate (DCR) of 69% in heavily pre-treated patients who have received a median of 3 prior lines of therapyPatient responses include sarcoma subtype...
November 17, 2022
LEXINGTON, Mass., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo Armen...
November 16, 2022
Overall response rates ranged from 22% in microsatellite stable colorectal cancer (MSS-CRC) to 60% in PD-(L)1 refractory non-small cell lung cancer (NSCLC)Initiated Phase 2 ACTIVATE trials of botensil...
November 14, 2022
Agenus ( NASDAQ:AGEN ) Third Quarter 2022 Results Key Financial Results Revenue: US$22.8m (down 91% from 3Q 2021). Net...
November 10, 2022
Thank you for holding, and welcome, everyone, to the Agenus third quarter 2022 financial results call. Now, I'd like to turn the call over to Garo to highlight our progress and speak to our outlook f...
November 8, 2022
Agenus (AGEN) delivered earnings and revenue surprises of -5.56% and 14.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
November 8, 2022
Company to present expanded data from Phase 1 study of botensilimab (Fc-enhanced anti-CTLA-4) at plenary session of the Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingInitiated Phase 2 ...
November 8, 2022
Agenus (AGEN) closed at $2.51 in the latest trading session, marking a -1.57% move from the prior day.
October 31, 2022
On Agenus' (AGEN) third-quarter earnings call, investor focus is likely to be on the company's progress with the developments of its pipeline candidates.
October 26, 2022
In the latest trading session, Agenus (AGEN) closed at $2.63, marking a +0.77% move from the previous day.
October 25, 2022
Next page